KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Goodwill (2016 - 2025)

Historic Goodwill for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $1.1 billion.

  • Vertex Pharmaceuticals' Goodwill changed 0.0% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.1 billion for FY2025, which is 0.0% changed from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Goodwill of $1.1 billion as of Q4 2025, which was down 0.0% from $1.1 billion recorded in Q3 2025.
  • Vertex Pharmaceuticals' 5-year Goodwill high stood at $1.1 billion for Q4 2022, and its period low was $1.0 billion during Q1 2021.
  • Its 5-year average for Goodwill is $1.1 billion, with a median of $1.1 billion in 2023.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Goodwill changed by 0.0% in 2021 and then surged by 975.85% in 2022.
  • Vertex Pharmaceuticals' Goodwill (Quarter) stood at $1.0 billion in 2021, then increased by 9.76% to $1.1 billion in 2022, then changed by 0.0% to $1.1 billion in 2023, then changed by 0.0% to $1.1 billion in 2024, then changed by 0.0% to $1.1 billion in 2025.
  • Its Goodwill was $1.1 billion in Q4 2025, compared to $1.1 billion in Q3 2025 and $1.1 billion in Q2 2025.